Chinese Hepatolgy ›› 2023, Vol. 28 ›› Issue (8): 983-986.

• Other Liver Diseases • Previous Articles     Next Articles

Effects of endoscopic ultrasound-guided percutaneous aspiration sclerotherapy on serum inflammatory factors in patients with hepatic cysts

WU Jian1, WANG Lian-cai2, WANG Ya-feng2, DU Chang-shun3, XIAO Jian-an4   

  1. 1. Department of General Surgery, Anyang Third People's Hospital, Henan 455000, China;
    2. Department of Hepatobiliary Pancreatic Surgery,Henan Provincial People's Hospital, Zhengzhou,450000, China;
    3. Department of General Surgery, Anyang People's Hospital,Henan 455000, China;
    4. Department of General Surgery, The Fourth Affiliated Hospital of Henan University of Science and Technology,Anyang 455000, China
  • Received:2022-09-29 Online:2023-08-31 Published:2023-09-21

PDF (PC)

78

Abstract: Objective To investigate the effects of endoscopic ultrasound (EUS)-guided aspiration combined with sclerotherapy on serum inflammatory factors in patients with hepatic cysts.Methods From June 2020 to June 2022, 90 patients with hepatic cysts were admitted to our hospital. These patients were randomly divided into control group and observation group, with each group comprising 45 patients, The control group underwent sclerosing agent injection, while the observation group received EUS-guided percutaneous aspiration sclerotherapy, for a duration of 48 weeks. The levels of blood biochemical indexes and inflammatory factors between the two groups pre-treatment and 7 days post-treatment were compared. Further more, the total effective rate and the incidence of adverse reactions 12 weeks post-treatment in both groups were analyzed. Lastly, the recurrence rate of hepatic cysts 48 weeks after treatment in both groups was observed in the two groups.Results At the 12-week post-treatment mark, the observation group showed a higher total effective rate of 95.56% compared to the control group`s 82.22%e (P<0.05). There were no significant differences in ALT, AST, ALP and TBil between the two groups 7 days post-treatment (P>0.05). In the observation group, the serum levels of CRP, TNF-α and IL-1β were significantly lower[(53.83±6.24) mg/L, (260.80±18.40) ng/L and (91.04±5.10) ng/L, respectively] than those in the control group [(56.67±5.96) mg/L, (268.92±16.93) ng/L and (93.22±4.87) ng/L, P<0.05]. The incidence of adverse reactions in the observation group (2.22%) was also lower than that in the control group (17.78% , P<0.05). At the end of the 48-week post-treatment period, the observation group showed a lower recurrence rate of hepatic cysts( 2.27%) compared to the control group(17.95%, P<0.05).Conclusion In comparison to sclerotherapy injection alone, EUS-guided percutaneous aspiration sclerotherapy proves to be more effective for hepatic cysts. This approach can mitigate inflammation, diminish the incidence of complications and recurrence, without significantly impacting liver function.

Key words: Endoscopic ultrasound, Fine needle aspiration, Sclerosing agent injection, Liver cyst, Serum inflammatory factor